PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Outlook Therapeutics Inc | OTLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.02 | 1.59% | 1.28 | 1.30 | 1.25 | 1.27 | 1.26 | 17:59:52 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.25 | 1.36 | 0.11 | 8.09% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 208 | 83,737 | $ 1.26 | $ 105,558 | 253,911 | 0.85 - 20.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:07:55 | 9 | $ 1.30 | USD |
Outlook Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 36.14M | 28.23M | $ -30.09M | -10.24 | - | 19.97M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 29.30% |
Outlook Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/15/2019 | 17:08 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
| 10/07/2019 | 18:12 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/07/2019 | 18:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/30/2019 | 17:44 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.31 | 1.43 | 1.25 | 1.34 | 99,065 | -0.03 | -2.29% |
| 1 Month | 1.72 | 1.73 | 1.21 | 1.42 | 135,033 | -0.44 | -25.58% |
| 3 Months | 2.30 | 2.38 | 1.21 | 1.70 | 276,315 | -1.02 | -44.35% |
| 6 Months | 1.62 | 4.08 | 0.85 | 2.31 | 2,748,946 | -0.34 | -20.99% |
| 1 Year | 5.60 | 20.00 | 0.85 | 2.56 | 1,727,750 | -4.32 | -77.14% |
| 3 Years | 5.60 | 20.00 | 0.85 | 2.56 | 1,727,750 | -4.32 | -77.14% |
| 5 Years | 5.60 | 20.00 | 0.85 | 2.56 | 1,727,750 | -4.32 | -77.14% |
Outlook Therapeutics Description
| Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. |
